Overall, there is no proven pharmacological therapy in ARDS, but some pharmacological
interventions were associated with beneficial effects in certain subgroups of patients …

The acute respiratory distress syndrome (ARDS) remains a common and highly morbid
condition despite advances in the understanding and management of this complex critical …

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are a complex
response of the lung to direct or indirect insults, characterized by sudden-onset severe …

Despite its high incidence and devastating outcomes, acute respiratory distress syndrome
(ARDS) has no specific treatment, with effective therapy currently limited to minimizing …

Objectives To outline both the preclinical and clinical data demonstrating surfactant
alterations in acute lung injury, which provide the rationale for testing exogenous surfactant …

The acute respiratory distress syndrome (ARDS) was first described by Ashbaugh and
colleagues in 1967. However, despite considerable efforts, early progress in treatment was …

The acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a clinical
syndrome that affects both medical and surgical patients. To date, despite improved …

The acute respiratory distress syndrome (ARDS) is a major cause of acute respiratory
failure. Its development leads to high rates of mortality, as well as short-and long-term …

Since acute respiratory distress syndrome (ARDS) was first described in 1967 there has
been large number of studies addressing its pathogenesis and therapies. Despite this …

Acute respiratory distress syndrome (ARDS) is characterized by acute diffuse lung injury,
which results in increased pulmonary vascular permeability and loss of aerated lung tissue …